{"id":50757,"date":"2022-11-11T13:02:30","date_gmt":"2022-11-11T12:02:30","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/caredx-committed-to-delivering-clinical-innovation-to-the-transplant-patient-and-physician-community\/"},"modified":"2022-11-11T13:02:30","modified_gmt":"2022-11-11T12:02:30","slug":"caredx-committed-to-delivering-clinical-innovation-to-the-transplant-patient-and-physician-community","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/caredx-committed-to-delivering-clinical-innovation-to-the-transplant-patient-and-physician-community\/","title":{"rendered":"CareDx Committed to Delivering Clinical Innovation to the Transplant Patient and Physician Community"},"content":{"rendered":"
\n

\nCareDx Leads Scientific Evidence with Over 100 Peer-Reviewed Publications Supporting the Clinical Use of AlloSure and AlloMap for Organ Transplant Patients<\/i>\n<\/p>\n

BRISBANE, Calif.–(BUSINESS WIRE)–CareDx, Inc. (Nasdaq: CDNA) \u2013 The Transplant Company\u2122 focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers \u2013 today announced the five-year anniversary of AlloSure\u00ae, the groundbreaking, non-invasive donor-derived cell-free DNA (dd-cfDNA) surveillance solution used to measure allograft injury in solid organ transplant recipients. AlloSure along with AlloMap\u00ae represent disruptive innovations in the field of solid organ transplant.\n<\/p>\n

<\/a><\/p>\n

\n\u201cPrior to AlloSure\u2019s introduction, dd-cfDNA was one of many non-invasive markers for organ rejection with the potential for clinical use. At the time, no one could have predicted the impact that it has achieved in just five years,\u201d said Matthew R. Weir, MD, Attending Physician and Director of the Division of Nephrology in the Department of Medicine, University of Maryland School of Medicine and University of Maryland Medical Center. \u201cCareDx led the way by demonstrating the value of dd-cfDNA by applying its extensive experience in organ transplant diagnostics to provide a clinically useful service with the power of dd-cfDNA to identify molecular signs of graft injury.\u201d\n<\/p>\n

\n\u201cAt CareDx, we are proud to have taken a leadership role in the field of transplant as very few companies are investing in transplant, let alone being 100 percent focused. Transplant is a lightly served area with research and development when compared to most other medical areas such as oncology, neurology and rare diseases. We have served this market, as the unmet need is significant, and it is estimated that one in five kidney transplants, one in three heart transplants, and one in two lung transplants are expected to fail five years post-transplant. There is an important need for highly sensitive and accurate biomarkers that can detect early injury and\/or changes in immune quiescence,\u201d said Reg Seeto, CEO and President of CareDx.\n<\/p>\n

\nFor more than twenty years CareDx has invested in transplant innovations to improve long-term allograft outcomes. This innovation has taken both significant financial investment and time to conduct multicenter, prospective studies versus relying only on single center or retrospective studies. In addition, CareDx has always conducted further clinical studies to build a robust scientific base of understanding for the transplant physician. Its tests are transplant specific and not repurposed from uses outside organ transplant.\n<\/p>\n

\nKey highlights:<\/b>\n<\/p>\n